{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:41:06Z","timestamp":1790847666052,"version":"4.1.0"},"reference-count":514,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is the most common neurodegenerative disorder with motor symptoms. The neuropathological alterations characterizing the brain of patients with PD include the loss of dopaminergic neurons of the nigrostriatal system and the presence of Lewy bodies (LB), intraneuronal inclusions that are mainly composed of alpha-synuclein (\u03b1-Syn) fibrils. The accumulation of \u03b1-Syn in insoluble aggregates is a main neuropathological feature in PD and in other neurodegenerative diseases, including LB dementia (LBD) and multiple system atrophy (MSA), which are therefore defined as synucleinopathies. Compelling evidence supports that \u03b1-Syn post translational modifications (PTMs) such as phosphorylation, nitration, acetylation, O-GlcNAcylation, glycation, SUMOylation, ubiquitination and C-terminal cleavage, play important roles in the modulation \u03b1-Syn aggregation, solubility, turnover and membrane binding. In particular, PTMs can impact on \u03b1-Syn conformational state, thus supporting that their modulation can in turn affect \u03b1-Syn aggregation and its ability to seed further soluble \u03b1-Syn fibrillation. This review focuses on the importance of \u03b1-Syn PTMs in PD pathophysiology but also aims at highlighting their general relevance as possible biomarkers and, more importantly, as innovative therapeutic targets for synucleinopathies. In addition, we call attention to the multiple challenges that we still need to face to enable the development of novel therapeutic approaches modulating \u03b1-Syn PTMs.<\/jats:p>","DOI":"10.3389\/fnmol.2023.1197853","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:15:32Z","timestamp":1684973732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Alpha synuclein post translational modifications: potential targets for Parkinson\u2019s disease therapy?"],"prefix":"10.3389","volume":"16","author":[{"given":"Viviana","family":"Brembati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Faustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Longhena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/mds.21560","article-title":"Bowel movement frequency in late-life and incidental Lewy bodies","volume":"22","author":"Abbott","year":"2007","journal-title":"Mov. Disord."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"11120","DOI":"10.1038\/srep11120","article-title":"Total and proteinase K-resistant alpha-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson's disease","volume":"5","author":"Abd-Elhadi","year":"2015","journal-title":"Sci. Rep."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1002\/acn3.50944","article-title":"Alpha-synuclein in blood cells differentiates Parkinson's disease from healthy controls","volume":"6","author":"Abd Elhadi","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jnc.13087","article-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways","volume":"133","author":"Abdelsalam","year":"2015","journal-title":"J. Neurochem."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrn1868","article-title":"Expanding insights of mitochondrial dysfunction in Parkinson's disease","volume":"7","author":"Abou-Sleiman","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.diabres.2004.09.004","article-title":"Advanced glycation endproducts--role in pathology of diabetic complications","volume":"67","author":"Ahmed","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"12334","DOI":"10.1074\/jbc.M110414200","article-title":"Alpha-synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells","volume":"277","author":"Ahn","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/bs.ircmb.2015.01.001","article-title":"Molecular, cellular, and physiological significance of N-terminal acetylation","volume":"316","author":"Aksnes","year":"2015","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1046\/j.1471-4159.1997.69031196.x","article-title":"Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra","volume":"69","author":"Alam","year":"1997","journal-title":"J. Neurochem."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/j.1471-4159.2009.06228.x","article-title":"The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide","volume":"110","author":"Albani","year":"2009","journal-title":"J. Neurochem."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1365-2990.2007.00888.x","article-title":"LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease","volume":"34","author":"Alegre-Abarrategui","year":"2008","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","article-title":"BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia","volume":"77","author":"Antelope","year":"2019","journal-title":"Exp. Hematol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1523\/JNEUROSCI.0341-06.2006","article-title":"The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease","volume":"26","author":"Arawaka","year":"2006","journal-title":"J. Neurosci."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fnagi.2020.00103","article-title":"Resveratrol derivatives as potential treatments for Alzheimer's and Parkinson's disease","volume":"12","author":"Arbo","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"683920","DOI":"10.1155\/2013\/683920","article-title":"Neuroprotective function of DJ-1 in Parkinson's disease","volume":"2013","author":"Ariga","year":"2013","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1753-6561-3-S6-S1","article-title":"Protein N-terminal acetylation: NAT 2007-2008 Symposia","volume":"3","author":"Arnesen","year":"2009","journal-title":"BMC Proc."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial","volume":"76","author":"Athauda","year":"","journal-title":"JAMA Neurol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ejn.14096","article-title":"Post hoc analysis of the exenatide-PD trial-factors that predict response","volume":"49","author":"Athauda","year":"","journal-title":"Eur. J. Neurosci."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JPD-181329","article-title":"What effects might exenatide have on non-motor symptoms in Parkinson's disease: a post hoc analysis","volume":"8","author":"Athauda","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.chembiol.2020.06.002","article-title":"Peptide-based PROTAC: the predator of pathological proteins","volume":"27","author":"Au","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11064-020-03186-w","article-title":"Idebenone ameliorates rotenone-induced Parkinson's disease in rats through decreasing lipid peroxidation","volume":"46","author":"Avci","year":"2021","journal-title":"Neurochem. Res."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"ref26","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/bmj.329.7466.611","article-title":"The journey: Parkinson's disease","volume":"329","author":"Baker","year":"2004","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.parkreldis.2022.05.009","article-title":"Methylation of alpha-synuclein in a Sudanese cohort","volume":"101","author":"Bakhit","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e2264","DOI":"10.1371\/annotation\/c54ef754-1962-4125-bf19-76d3ec6f19e5","article-title":"A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice","volume":"3","author":"Barger","year":"2008","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","article-title":"Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels","year":"2011","journal-title":"Nature"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e103727","DOI":"10.1371\/journal.pone.0103727","article-title":"N-alpha-acetylation of alpha-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation","volume":"9","author":"Bartels","year":"2014","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1002\/ana.410440716","article-title":"Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis","volume":"44","author":"Beal","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1146\/annurev.nutr.23.020102.075739","article-title":"Iron status and neural functioning","volume":"23","author":"Beard","year":"2003","journal-title":"Annu. Rev. Nutr."},{"key":"ref35","article-title":"Effects of N-terminal acetylation on the aggregation of disease-related alpha-synuclein variants","volume":"167825","author":"Bell","year":"","journal-title":"J. Mol. Biol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"167825","DOI":"10.1016\/j.jmb.2022.167825","article-title":"Effects of N-terminal acetylation on the aggregation of disease-related alpha-synuclein variants","volume":"435","author":"Bell","year":"2023","journal-title":"J. Mol. Biol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1021\/acs.biochem.2c00104","article-title":"N-terminal acetylation of alpha-synuclein slows down its aggregation process and alters the morphology of the resulting aggregates","volume":"61","author":"Bell","year":"","journal-title":"Biochemistry"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"661117","DOI":"10.3389\/fneur.2021.661117","article-title":"Modulation of the interactions between alpha-synuclein and lipid membranes by Post-translational modifications","volume":"12","author":"Bell","year":"2021","journal-title":"Front. Neurol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fnagi.2017.00330","article-title":"The end is the beginning: Parkinson's disease in the light of brain imaging","volume":"9","author":"Bellucci","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/nan.12297","article-title":"Review: Parkinson's disease: from synaptic loss to connectome dysfunction","volume":"42","author":"Bellucci","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.brainres.2011.11.031","article-title":"Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease","volume":"1432","author":"Bellucci","year":"2012","journal-title":"Brain Res."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"33855","DOI":"10.1074\/jbc.274.48.33855","article-title":"Degradation of alpha-synuclein by proteasome","volume":"274","author":"Bennett","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mds.1120","article-title":"Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy","volume":"16","author":"Boeve","year":"2001","journal-title":"Mov. Disord."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"27233","DOI":"10.1074\/jbc.M402273200","article-title":"A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus","volume":"279","author":"Bohren","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev-nutr-071812-161240","article-title":"O-GlcNAc cycling: a link between metabolism and chronic disease","volume":"33","author":"Bond","year":"2013","journal-title":"Annu. Rev. Nutr."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e84442","DOI":"10.1371\/journal.pone.0084442","article-title":"Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice","volume":"8","author":"Borghgraef","year":"2013","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00702-019-02062-4","article-title":"Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review","volume":"126","author":"Bougea","year":"","journal-title":"J. Neural Transm. (Vienna)"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"40","author":"Bougea","year":"","journal-title":"Neurol. Sci."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1172\/JCI85456","article-title":"Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration","volume":"126","author":"Brahmachari","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.cmet.2022.02.001","article-title":"The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease","volume":"34","author":"Brakedal","year":"2022","journal-title":"Cell Metab."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/mds.27128","article-title":"Glitazone use associated with reduced risk of Parkinson's disease","volume":"32","author":"Brakedal","year":"2017","journal-title":"Mov. Disord."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"35631","DOI":"10.1074\/jbc.M005401200","article-title":"c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines","volume":"275","author":"Brasher","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e1001854","DOI":"10.1371\/journal.pmed.1001854","article-title":"Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study","volume":"12","author":"Brauer","year":"2015","journal-title":"PLoS Med."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41531-021-00195-6","article-title":"Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors","volume":"7","author":"Braun","year":"2021","journal-title":"NPJ Parkinsons Dis."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/j.1742-4658.2007.05917.x","article-title":"Interactions between metals and alpha-synuclein--function or artefact?","volume":"274","author":"Brown","year":"2007","journal-title":"FEBS J."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cmet.2014.11.003","article-title":"Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss","volume":"20","author":"Brown","year":"2014","journal-title":"Cell Metab."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1021\/acschemneuro.7b00250","article-title":"N-terminal acetylation preserves alpha-Synuclein from Oligomerization by blocking intermolecular hydrogen bonds","volume":"8","author":"Bu","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Burre","year":"2010","journal-title":"Science"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbagen.2009.07.018","article-title":"O-linked beta-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress","volume":"1800","author":"Butkinaree","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1471-4159.2001.00021.x","article-title":"The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease","volume":"76","author":"Campbell","year":"2001","journal-title":"J. Neurochem."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.cmet.2012.04.022","article-title":"The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity","volume":"15","author":"Canto","year":"2012","journal-title":"Cell Metab."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12017-017-8447-9","article-title":"Deferiprone rescues behavioral deficits induced by mild Iron exposure in a mouse model of alpha-synuclein aggregation","volume":"19","author":"Carboni","year":"2017","journal-title":"NeuroMolecular Med."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3389\/fnins.2019.00889","article-title":"Phospho-S129 alpha-synuclein is present in human plasma but not in cerebrospinal fluid as determined by an ultrasensitive immunoassay","volume":"13","author":"Cariulo","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"11332","DOI":"10.1073\/pnas.90.23.11332","article-title":"Helix capping propensities in peptides parallel those in proteins","volume":"90","author":"Chakrabartty","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"Rejuvenation' protects neurons in mouse models of Parkinson's disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bbrc.2021.08.049","article-title":"Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative","volume":"574","author":"Chau","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.abb.2013.02.009","article-title":"Oxidation and nitration of alpha-synuclein and their implications in neurodegenerative diseases","volume":"533","author":"Chavarria","year":"2013","journal-title":"Arch. Biochem. Biophys."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1172\/JCI39088","article-title":"Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation","volume":"119","author":"Chen","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neuroscience.2007.06.053","article-title":"Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity","volume":"149","author":"Chen","year":"2007","journal-title":"Neuroscience"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"13953","DOI":"10.1038\/s41598-018-31455-w","article-title":"Author correction: post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1476-5381.2011.01575.x","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage","volume":"165","author":"Chen","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neulet.2010.09.061","article-title":"Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo","volume":"486","author":"Chinta","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1073\/pnas.1218424110","article-title":"Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking","volume":"110","author":"Choi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neurobiolaging.2015.10.001","article-title":"A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson's disease","volume":"37","author":"Choong","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/mds.26473","article-title":"Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: limited role as a biomarker","volume":"31","author":"Chung","year":"2016","journal-title":"Mov. Disord."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e12333","DOI":"10.1371\/journal.pone.0012333","article-title":"Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice","volume":"5","author":"Clark","year":"2010","journal-title":"PLoS One"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0166-2236(97)01213-7","article-title":"The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease","volume":"21","author":"Clayton","year":"1998","journal-title":"Trends Neurosci."},{"key":"ref001","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1021\/acschembio.8b00466","article-title":"Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase","volume":"305","author":"Cohen","year":"2004","journal-title":"Science"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1046\/j.1471-4159.2001.00655.x","article-title":"Cytosolic O-glycosylation is abundant in nerve terminals","volume":"79","author":"Cole","year":"2001","journal-title":"J. Neurochem."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"bcr2013009289","DOI":"10.1136\/bcr-2013-009289","article-title":"High-dose thiamine as initial treatment for Parkinson's disease","volume":"2013","author":"Costantini","year":"2013","journal-title":"BMJ Case Rep."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1089\/acm.2014.0353","article-title":"Long-term treatment with high-dose thiamine in Parkinson disease: an open-label pilot study","volume":"21","author":"Costantini","year":"2015","journal-title":"J. Altern. Complement. Med."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fasebj.13.12.1537","article-title":"Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats","volume":"13","author":"Crespo","year":"1999","journal-title":"FASEB J."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0014-5793(98)01146-6","article-title":"Synthetic filaments assembled from C-terminally truncated alpha-synuclein","volume":"436","author":"Crowther","year":"1998","journal-title":"FEBS Lett."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.bbamcr.2007.03.010","article-title":"p38 MAP-kinases pathway regulation, function and role in human diseases","volume":"1773","author":"Cuenda","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"7823","DOI":"10.1021\/ac901176t","article-title":"Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease","volume":"81","author":"Danielson","year":"2009","journal-title":"Anal. Chem."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"14524","DOI":"10.1073\/pnas.172514599","article-title":"Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP","volume":"99","author":"Dauer","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ana.26550","article-title":"A combined panel of salivary biomarkers in de novo Parkinson's disease","volume":"93","author":"De Bartolo","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"e1002601","DOI":"10.1371\/journal.pbio.1002601","article-title":"Correction: the mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease","volume":"15","author":"De Oliveira","year":"2017","journal-title":"PLoS Biol."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/archneur.1997.00550180070015","article-title":"Dietary antioxidants and Parkinson disease. The rotterdam study","volume":"54","author":"De Rijk","year":"1997","journal-title":"Arch. Neurol."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.nbd.2011.12.013","article-title":"Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons","volume":"45","author":"Decressac","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1182\/blood-2005-09-3691","article-title":"Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding","volume":"108","author":"Deng","year":"2006","journal-title":"Blood"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"Denicola","year":"2011","journal-title":"Nature"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1093\/brain\/awr015","article-title":"Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease","volume":"134","author":"Devic","year":"2011","journal-title":"Brain"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","article-title":"Trial of Deferiprone in Parkinson's Disease","volume":"387","author":"Devos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"342ra78","DOI":"10.1126\/scitranslmed.aaf3634","article-title":"Alpha-synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease","volume":"8","author":"Di Maio","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1021\/acschembio.6b00539","article-title":"Semisynthetic and in vitro phosphorylation of alpha-synuclein at Y39 promotes functional partly helical membrane-bound states resembling those induced by PD mutations","volume":"11","author":"Dikiy","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"14246","DOI":"10.1038\/s41598-018-32588-8","article-title":"Skin alpha-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study","volume":"8","author":"Donadio","year":"2018","journal-title":"Sci. Rep."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1212\/WNL.0000000000000316","article-title":"Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease","volume":"82","author":"Donadio","year":"2014","journal-title":"Neurology"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3748\/wjg.v9.i6.1307","article-title":"Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis","volume":"9","author":"Dong","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1523\/JNEUROSCI.3442-11.2012","article-title":"SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones","volume":"32","author":"Donmez","year":"2012","journal-title":"J. Neurosci."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1091\/mbc.e10-03-0200","article-title":"Drosophila histone deacetylase 6 protects dopaminergic neurons against alpha-synuclein toxicity by promoting inclusion formation","volume":"21","author":"Du","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.neurobiolaging.2014.04.029","article-title":"Histone deacetylase 6 regulates cytotoxic alpha-synuclein accumulation through induction of the heat shock response","volume":"35","author":"Du","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2353\/ajpath.2007.061232","article-title":"Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation","volume":"170","author":"Dufty","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.neurobiolaging.2013.11.001","article-title":"Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease","volume":"35","author":"Dunn","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1002\/mnfr.200700249","article-title":"Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2","volume":"52","author":"Eggler","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"ref109","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.bbamcr.2016.12.002","article-title":"Iron mediated toxicity and programmed cell death: a review and a re-examination of existing paradigms","volume":"1864","author":"Eid","year":"2017","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"ref110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1432-1327.1998.2580157.x","article-title":"The N-terminal region of non-a beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils","volume":"258","author":"El-Agnaf","year":"","journal-title":"Eur. J. Biochem."},{"key":"ref111","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-5793(98)01418-5","article-title":"Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments","volume":"440","author":"El-Agnaf","year":"","journal-title":"FEBS Lett."},{"key":"ref112","doi-asserted-by":"publisher","first-page":"104583","DOI":"10.1016\/j.neuint.2019.104583","article-title":"Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes","volume":"131","author":"Elbassuoni","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"10190","DOI":"10.1128\/MCB.25.22.10190-10201.2005","article-title":"Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein","volume":"25","author":"Ellis","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref114","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1074\/jbc.M010316200","article-title":"Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases","volume":"276","author":"Ellis","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref115","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.neurobiolaging.2008.07.008","article-title":"Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome","volume":"31","author":"Emmanouilidou","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tins.2016.10.008","article-title":"The threshold theory for Parkinson's Disease","volume":"40","author":"Engelender","year":"2017","journal-title":"Trends Neurosci."},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/mds.29058","article-title":"Can we treat neurodegenerative Proteinopathies by enhancing protein degradation?","volume":"37","author":"Engelender","year":"2022","journal-title":"Mov. Disord."},{"key":"ref118","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13008-015-0010-1","article-title":"Sumo and the cellular stress response","volume":"10","author":"Enserink","year":"2015","journal-title":"Cell Div"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(05)70097-1","article-title":"Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis","volume":"4","author":"Etminan","year":"2005","journal-title":"Lancet Neurol."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00401-018-1892-1","article-title":"Synapsin III deficiency hampers alpha-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease","volume":"136","author":"Faustini","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref121","doi-asserted-by":"publisher","first-page":"4246350","DOI":"10.1155\/2019\/4246350","article-title":"Alpha-Synuclein preserves mitochondrial fusion and function in neuronal cells","volume":"2019","author":"Faustini","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref122","doi-asserted-by":"publisher","first-page":"28243","DOI":"10.1074\/jbc.M112.383711","article-title":"Characterization of semisynthetic and naturally Nalpha-acetylated alpha-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of alpha-synuclein","volume":"287","author":"Fauvet","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref123","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jnc.14809","article-title":"Parkinson's disease biomarkers based on alpha-synuclein","volume":"150","author":"Fayyad","year":"2019","journal-title":"J. Neurochem."},{"key":"ref124","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/35006074","article-title":"A Drosophila model of Parkinson's disease","volume":"404","author":"Feany","year":"2000","journal-title":"Nature"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nbd.2019.05.002","article-title":"Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification","volume":"129","author":"Fenyi","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref126","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/sj.emboj.7600211","article-title":"NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation","volume":"23","author":"Fernandez","year":"2004","journal-title":"EMBO J."},{"key":"ref128","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1089\/ars.2013.5250","article-title":"May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125\/136 nitrosylation of serum alpha-synuclein serve for diagnosis of sporadic Parkinson's disease?","volume":"19","author":"Fernandez","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref129","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","article-title":"Targeting alpha-Synuclein as a therapy for Parkinson's Disease","volume":"12","author":"Fields","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2013.02.012","article-title":"Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei","volume":"269","author":"Fitzgerald","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref131","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.2337\/db07-0697","article-title":"Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice","volume":"56","author":"Flock","year":"2007","journal-title":"Diabetes"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1471-4159.1998.70010268.x","article-title":"Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay","volume":"70","author":"Floor","year":"1998","journal-title":"J. Neurochem."},{"key":"ref133","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.freeradbiomed.2013.05.045","article-title":"How do nutritional antioxidants really work: nucleophilic tone and Para-hormesis versus free radical scavenging in vivo","volume":"66","author":"Forman","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref134","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41573-021-00267-5","article-title":"Author correction: targeting oxidative stress in disease: promise and limitations of antioxidant therapy","volume":"20","author":"Forman","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref135","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1124\/jpet.114.219345","article-title":"MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3\/REST complex on the synapsin-1 promoter","volume":"352","author":"Formisano","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref136","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.tcb.2003.09.001","article-title":"Proteasome degradation: enter the substrate","volume":"13","author":"Forster","year":"2003","journal-title":"Trends Cell Biol."},{"key":"ref137","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1586\/erm.12.5","article-title":"Phosphorylated alpha-synuclein as a potential biomarker for Parkinson's disease and related disorders","volume":"12","author":"Foulds","year":"2012","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref138","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci. Rep."},{"key":"ref139","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1096\/fj.10-179192","article-title":"Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease","volume":"25","author":"Foulds","year":"2011","journal-title":"FASEB J."},{"key":"ref140","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","article-title":"Alpha-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref141","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.chembiol.2009.01.009","article-title":"Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate","volume":"16","author":"Fukuda","year":"2009","journal-title":"Chem. Biol."},{"key":"ref142","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/nen.0b013e3180517454","article-title":"Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease","volume":"66","author":"Fumimura","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref143","doi-asserted-by":"publisher","first-page":"702639","DOI":"10.3389\/fnagi.2021.702639","article-title":"Alpha-synuclein as a biomarker of Parkinson's disease: good, but not good enough","volume":"13","author":"Ganguly","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref144","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1385\/NMM:5:3:235","article-title":"Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity","volume":"5","author":"Gardian","year":"2004","journal-title":"NeuroMolecular Med."},{"key":"ref145","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/mds.25776","article-title":"Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders","volume":"29","author":"Gelpi","year":"2014","journal-title":"Mov. Disord."},{"key":"ref146","doi-asserted-by":"publisher","first-page":"Reviews3002","DOI":"10.1186\/gb-2001-3-1-reviews3002","article-title":"The Synucleins","volume":"3","author":"George","year":"2002","journal-title":"Genome Biol."},{"key":"ref147","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3390\/antiox9111156","article-title":"Redox potential of antioxidants in cancer progression and prevention","volume":"9","author":"George","year":"2020","journal-title":"Antioxidants"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF03033371","article-title":"Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease","volume":"5","author":"Gerlach","year":"2003","journal-title":"Neurotox. Res."},{"key":"ref149","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12640-020-00238-5","article-title":"Butyrate protects against salsolinol-induced toxicity in SH-SY5Y cells: implication for Parkinson's disease","volume":"38","author":"Getachew","year":"2020","journal-title":"Neurotox. Res."},{"key":"ref150","doi-asserted-by":"publisher","first-page":"e2109617119","DOI":"10.1073\/pnas.2109617119","article-title":"Alpha-synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity","volume":"119","author":"Ghanem","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref151","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fneur.2018.00295","article-title":"Alpha-Synuclein: from early synaptic dysfunction to Neurodegeneration","volume":"9","author":"Ghiglieri","year":"2018","journal-title":"Front. Neurol."},{"key":"ref152","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1006\/exnr.2001.7805","article-title":"Prominent perikaryal expression of alpha-and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons","volume":"172","author":"Giasson","year":"2001","journal-title":"Exp. Neurol."},{"key":"ref153","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.290.5493.985","article-title":"Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions","volume":"290","author":"Giasson","year":"2000","journal-title":"Science"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and synergistic fibrillization of tau and alpha-synuclein","volume":"300","author":"Giasson","year":"2003","journal-title":"Science"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2990.1986.tb00136.x","article-title":"Idiopathic Parkinson's disease and the Lewy body disorders","volume":"12","author":"Gibb","year":"1986","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref156","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1096\/fasebj.12.9.685","article-title":"Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation","volume":"12","author":"Gilad","year":"1998","journal-title":"FASEB J."},{"key":"ref157","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1196\/annals.1296.066","article-title":"Oxidative stress to dopaminergic neurons as models of Parkinson's disease","volume":"1018","author":"Gille","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref158","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.neuroscience.2008.02.061","article-title":"Differential activation of mitogen-activated protein kinase signalling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer's disease","volume":"153","author":"GioVannini","year":"2008","journal-title":"Neuroscience"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1006\/nbdi.2002.0538","article-title":"Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway","volume":"11","author":"Giovannini","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref160","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1038\/ncomms6245","article-title":"Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations","volume":"5","author":"Godena","year":"2014","journal-title":"Nat. Commun."},{"key":"ref161","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","article-title":"The synucleinopathies: twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"ref162","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s004010051135","article-title":"Alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining","volume":"99","author":"Gomez-Tortosa","year":"2000","journal-title":"Acta Neuropathol."},{"key":"ref163","doi-asserted-by":"publisher","first-page":"683097","DOI":"10.1155\/2012\/683097","article-title":"Oxidative stress, DNA damage, and c-Abl signaling: at the crossroad in neurodegenerative diseases?","volume":"2012","author":"Gonfloni","year":"2012","journal-title":"Int. J. Cell. Biol."},{"key":"ref164","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.neurobiolaging.2012.12.005","article-title":"Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models","volume":"34","author":"Gong","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"17319","DOI":"10.1073\/pnas.1215395109","article-title":"O-GlcNAc cycling modulates neurodegeneration","volume":"109","author":"Gong","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref166","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1073\/pnas.0711053105","article-title":"The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease","volume":"105","author":"Gorbatyuk","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref167","doi-asserted-by":"publisher","first-page":"e52312","DOI":"10.1371\/journal.pone.0052312","article-title":"Alphalpha-synuclein levels in blood plasma from LRRK2 mutation carriers","volume":"7","author":"Gorostidi","year":"2012","journal-title":"PLoS One"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0306-4522(83)90137-9","article-title":"Intracellular and extracellular electrophysiology of nigral dopaminergic neurons\u20143. Evidence for electrotonic coupling","volume":"10","author":"Grace","year":"1983","journal-title":"Neuroscience"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.neuropharm.2013.11.025","article-title":"Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy","volume":"79","author":"Graham","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1126\/science.1098966","article-title":"Biomedicine. Parkinson's--divergent causes, convergent mechanisms","volume":"304","author":"Greenamyre","year":"2004","journal-title":"Science"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/bi400199p","article-title":"NMR structure of calmodulin complexed to an N-terminally acetylated alpha-synuclein peptide","volume":"52","author":"Gruschus","year":"2013","journal-title":"Biochemistry"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"101812","DOI":"10.1016\/j.redox.2020.101812","article-title":"Idebenone: when an antioxidant is not an antioxidant","volume":"38","author":"Gueven","year":"2021","journal-title":"Redox Biol."},{"key":"ref173","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/mnfr.201600111","article-title":"Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of alpha-synuclein via SIRT1-deacetylated LC3","volume":"60","author":"Guo","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"key":"ref174","doi-asserted-by":"publisher","first-page":"12375","DOI":"10.1128\/JVI.01545-10","article-title":"Induction of a cross-reactive CD8(+) T cell response following foot-and-mouth disease virus vaccination","volume":"84","author":"Guzman","year":"2010","journal-title":"J. Virol."},{"key":"ref175","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2217\/bmm-2019-0167","article-title":"Oligomeric alpha-synuclein is increased in basal tears of Parkinson's patients","volume":"13","author":"Hamm-Alvarez","year":"2019","journal-title":"Biomark. Med"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"134910","DOI":"10.1016\/j.neulet.2020.134910","article-title":"Nicotinamide riboside protects noise-induced hearing loss by recovering the hair cell ribbon synapses","volume":"725","author":"Han","year":"2020","journal-title":"Neurosci. Lett."},{"key":"ref177","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.cub.2004.02.004","article-title":"Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission","volume":"14","author":"Harder","year":"2004","journal-title":"Curr. Biol."},{"key":"ref178","doi-asserted-by":"publisher","first-page":"113219","DOI":"10.1016\/j.expneurol.2020.113219","article-title":"Evaluation of the NAD(+) biosynthetic pathway in ALS patients and effect of modulating NAD(+) levels in hSOD1-linked ALS mouse models","volume":"327","author":"Harlan","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref179","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.tcb.2020.03.002","article-title":"The complex interplay between antioxidants and ROS in Cancer","volume":"30","author":"Harris","year":"2020","journal-title":"Trends Cell Biol."},{"key":"ref180","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1111\/bph.13208","article-title":"Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors","volume":"172","author":"Harrison","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref181","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neulet.2017.12.037","article-title":"Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition","volume":"666","author":"Harrison","year":"2018","journal-title":"Neurosci. Lett."},{"key":"ref182","doi-asserted-by":"publisher","first-page":"49071","DOI":"10.1074\/jbc.M208046200","article-title":"Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions","volume":"277","author":"Hasegawa","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref183","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-017-0181-0","article-title":"Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice","volume":"12","author":"Hastings","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"ref184","doi-asserted-by":"publisher","first-page":"8548380","DOI":"10.1155\/2021\/8548380","article-title":"Idebenone-activating Autophagic degradation of alpha-synuclein via inhibition of AKT-mTOR pathway in a SH-SY5Y-A53T model of Parkinson's disease: a network pharmacological approach","volume":"2021","author":"He","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref185","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/nchembio.2463","article-title":"Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor","volume":"13","author":"He","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref186","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1021\/acschemneuro.8b00288","article-title":"Alpha-synuclein nitration and its implications in Parkinson's disease","volume":"10","author":"He","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref187","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref188","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1212\/WNL.47.3.644","article-title":"Diet and Parkinson's disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study","volume":"47","author":"Hellenbrand","year":"1996","journal-title":"Neurology"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10719-016-9694-y","article-title":"Pathways of the Maillard reaction under physiological conditions","volume":"33","author":"Henning","year":"2016","journal-title":"Glycoconj. J."},{"key":"ref190","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"ref191","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41598-018-19664-9","article-title":"New 5-aryl-substituted 2-aminobenzamide-type HDAC inhibitors with a diketopiperazine group and their ameliorating effects on ischemia-induced neuronal cell death","volume":"8","author":"Hirata","year":"2018","journal-title":"Sci. Rep."},{"key":"ref192","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1021\/cb400630z","article-title":"Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2","volume":"8","author":"HIrohama","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref193","doi-asserted-by":"publisher","first-page":"47746","DOI":"10.1074\/jbc.M408906200","article-title":"Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation","volume":"279","author":"Hodara","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref194","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s0096-5332(08)60392-6","article-title":"The Amadori rearrangement","volume":"10","author":"Hodge","year":"1955","journal-title":"Adv. Carbohydr. Chem."},{"key":"ref195","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","article-title":"N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases","volume":"36","author":"Holmay","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"ref196","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref197","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease","volume":"133","author":"Hong","year":"2010","journal-title":"Brain"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0891-0618(01)00100-4","article-title":"Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease","volume":"22","author":"Hornykiewicz","year":"2001","journal-title":"J. Chem. Neuroanat."},{"key":"ref199","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1210\/en.2003-0163","article-title":"Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease","volume":"144","author":"Horvath","year":"2003","journal-title":"Endocrinology"},{"key":"ref200","doi-asserted-by":"publisher","first-page":"16233","DOI":"10.1021\/bi048453u","article-title":"Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro","volume":"43","author":"Hoyer","year":"2004","journal-title":"Biochemistry"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/tox.22920","article-title":"Protective effects of valproic acid on 6-hydroxydopamine-induced neuroinjury","volume":"35","author":"Hsu","year":"2020","journal-title":"Environ. Toxicol."},{"key":"ref202","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/mds.26819","article-title":"Intake of antioxidant vitamins and risk of Parkinson's disease","volume":"31","author":"Hughes","year":"2016","journal-title":"Mov. Disord."},{"key":"ref203","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/00043764-199009000-00011","article-title":"Principles of bladder cancer screening in an intervention trial","volume":"32","author":"Hulka","year":"1990","journal-title":"J. Occup. Med."},{"key":"ref204","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-1746786\/v1","article-title":"Effect of melatonin on alpha synuclein and autophagy in dopaminergic neuronal differentiation of adipose mesenchymal stem cells","volume-title":"Res. Sq.","author":"Ibrahim","year":"2022"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1523\/JNEUROSCI.1833-10.2011","article-title":"Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease","volume":"31","author":"Imam","year":"2011","journal-title":"J. Neurosci."},{"key":"ref206","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/jnen\/nlaa048","article-title":"A longitudinal skin biopsy study of phosphorylated alpha-synuclein in a patient with Parkinson disease and orthostatic hypotension","volume":"79","author":"Infante","year":"2020","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref207","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1074\/jbc.C800206200","article-title":"Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system","volume":"284","author":"Inglis","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref208","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/antiox8080244","article-title":"Strategies to improve resveratrol systemic and topical bioavailability: an update","volume":"8","author":"Intagliata","year":"2019","journal-title":"Antioxidants"},{"key":"ref209","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/cns.13609","article-title":"Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease","volume":"27","author":"Iravanpour","year":"2021","journal-title":"CNS Neurosci. Ther."},{"key":"ref210","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1212\/WNL.66.10_suppl_4.S24","article-title":"The pathogenesis of cell death in Parkinson's disease","volume":"66","author":"Jenner","year":"2006","journal-title":"Neurology"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"25481","DOI":"10.1074\/jbc.274.36.25481","article-title":"Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356","volume":"274","author":"Jensen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref212","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/brain\/awab015","article-title":"Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease","volume":"144","author":"Jeong","year":"2021","journal-title":"Brain"},{"key":"ref213","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1039\/C8FO02471E","article-title":"Vitamin B12 inhibits alpha-synuclein fibrillogenesis and protects against amyloid-induced cytotoxicity","volume":"10","author":"Jia","year":"2019","journal-title":"Food Funct."},{"key":"ref214","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neulet.2017.08.029","article-title":"Inhibition of HDAC6 increases acetylation of peroxiredoxin1\/2 and ameliorates 6-OHDA induced dopaminergic injury","volume":"658","author":"Jian","year":"2017","journal-title":"Neurosci. Lett."},{"key":"ref215","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s42003-021-01746-6","article-title":"Development of an alpha-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models","volume":"4","author":"Jin","year":"2021","journal-title":"Commun. Biol."},{"key":"ref216","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.parkreldis.2012.07.001","article-title":"RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study","volume":"19","author":"Johnston","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref217","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.2174\/138161211798072463","article-title":"Importance of iron chelation in free radical-induced oxidative stress and human disease","volume":"17","author":"Jomova","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref218","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1021\/acschembio.7b00489","article-title":"Small molecule enhancement of 20S proteasome activity targets intrinsically disordered proteins","volume":"12","author":"Jones","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref219","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0304-3940(02)00016-2","article-title":"Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine","volume":"320","author":"Junn","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref220","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.physbeh.2018.01.028","article-title":"Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: role of toll-like receptor 4, TGF-beta1, NF-kappaB and glucagon-like peptide 1","volume":"188","author":"Kabel","year":"2018","journal-title":"Physiol. Behav."},{"key":"ref221","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1749-6632.2000.tb06902.x","article-title":"Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein","volume":"920","author":"Kahle","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref222","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/pro.2088","article-title":"N-terminal acetylation of alpha-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer","volume":"21","author":"Kang","year":"2012","journal-title":"Protein Sci."},{"key":"ref223","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1007\/s00125-010-1722-z","article-title":"Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes","volume":"53","author":"Karachalias","year":"2010","journal-title":"Diabetologia"},{"key":"ref224","doi-asserted-by":"publisher","first-page":"16533","DOI":"10.1038\/s41598-017-15813-8","article-title":"Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice","volume":"7","author":"Karampetsou","year":"2017","journal-title":"Sci. Rep."},{"key":"ref225","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","article-title":"PROTAC compounds targeting alpha-synuclein protein for treating neurogenerative disorders: Alzheimer's and Parkinson's diseases","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref226","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci. Rep."},{"key":"ref227","doi-asserted-by":"crossref","first-page":"eabp9352","DOI":"10.1126\/scitranslmed.abp9352","article-title":"The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease","volume":"15","author":"Karuppagounder","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref228","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neulet.2008.02.057","article-title":"Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro","volume":"436","author":"Kasai","year":"2008","journal-title":"Neurosci. Lett."},{"key":"ref229","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","article-title":"Metformin lowers alpha-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease","volume":"125","author":"Katila","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref230","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cells"},{"key":"ref231","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/archneur.65.12.1577","article-title":"Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease","volume":"65","author":"Kazantsev","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref232","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1523\/JNEUROSCI.0984-06.2006","article-title":"Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled","volume":"26","author":"Keeney","year":"2006","journal-title":"J. Neurosci."},{"key":"ref233","first-page":"137","article-title":"Oxidative stress-related biomarkers in Parkinson's disease: a systematic review and meta-analysis","volume":"17","author":"Khan","year":"2018","journal-title":"Iran. J. Neurol."},{"key":"ref234","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.brainres.2010.07.041","article-title":"Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition","volume":"1354","author":"Kidd","year":"2010","journal-title":"Brain Res."},{"key":"ref235","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neuroscience.2011.08.010","article-title":"Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"194","author":"Kidd","year":"2011","journal-title":"Neuroscience"},{"key":"ref236","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1212\/WNL.44.9.1756","article-title":"The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson study group","volume":"44","author":"Kieburtz","year":"1994","journal-title":"Neurology"},{"key":"ref237","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1038\/sj.emboj.7601758","article-title":"SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis","volume":"26","author":"Kim","year":"2007","journal-title":"EMBO J."},{"key":"ref238","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1177\/0963689717721234","article-title":"A new treatment strategy for Parkinson's disease through the gut-brain axis: the glucagon-like peptide-1 receptor pathway","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Transplant."},{"key":"ref239","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5607\/en.2019.28.4.504","article-title":"HDAC inhibition by valproic acid induces neuroprotection and improvement of PD-like behaviors in LRRK2 R1441G transgenic mice","volume":"28","author":"Kim","year":"2019","journal-title":"Exp. Neurobiol."},{"key":"ref240","doi-asserted-by":"publisher","first-page":"16691","DOI":"10.1073\/pnas.1006083107","article-title":"Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function","volume":"107","author":"Ko","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref241","doi-asserted-by":"publisher","first-page":"e0123444","DOI":"10.1371\/journal.pone.0123444","article-title":"Alpha-synuclein levels in blood plasma decline with healthy aging","volume":"10","author":"Koehler","year":"2015","journal-title":"PLoS One"},{"key":"ref242","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fnins.2020.00682","article-title":"Elucidating the relationship between diabetes mellitus and Parkinson's disease using (18) F-FP-(+)-DTBZ, a positron-emission tomography probe for vesicular monoamine transporter 2","volume":"14","author":"Kong","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref243","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/JPD-171285","article-title":"Alpha-synuclein glycation and the action of anti-diabetic agents in Parkinson's disease","volume":"8","author":"Konig","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"ref244","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnins.2020.00682","article-title":"Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes","volume":"19","author":"Kopytek","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref245","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fmolb.2019.00048","article-title":"Regulation of proteasome activity by (Post-)transcriptional mechanisms","volume":"6","author":"Kors","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"ref246","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1021\/cn5002254","article-title":"Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event","volume":"5","author":"Kosten","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"ref247","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1083\/jcb.201010117","article-title":"Sumoylation inhibits alpha-synuclein aggregation and toxicity","volume":"194","author":"Krumova","year":"2011","journal-title":"J. Cell Biol."},{"key":"ref248","doi-asserted-by":"publisher","first-page":"fcac165","DOI":"10.1093\/braincomms\/fcac165","article-title":"Linking alpha-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson's disease","volume":"4","author":"Kulkarni","year":"2022","journal-title":"Brain Commun."},{"key":"ref249","doi-asserted-by":"publisher","first-page":"e2012171118","DOI":"10.1073\/pnas.2012171118","article-title":"Structural insights into alpha-synuclein monomer-fibril interactions","volume":"118","author":"Kumari","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref250","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/1531-8257(199905)14:3<507::AID-MDS1021>3.0.CO;2-8","article-title":"Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation","volume":"14","author":"Kunz","year":"1999","journal-title":"Mov. Disord."},{"key":"ref251","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1210\/jc.2002-021057","article-title":"Melatonin in patients with reduced REM sleep duration: two randomized controlled trials","volume":"89","author":"Kunz","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref252","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13024-016-0125-0","article-title":"A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein","volume":"11","author":"Landeck","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref253","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cbpa.2021.05.006","article-title":"Rethinking protein aggregation and drug discovery in neurodegenerative diseases: why we need to embrace complexity?","volume":"64","author":"Lashuel","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref254","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1101\/gr.8.9.871","article-title":"The synuclein family","volume":"8","author":"Lavedan","year":"1998","journal-title":"Genome Res."},{"key":"ref255","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/hmg\/ddm363","article-title":"Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death","volume":"17","author":"Lee","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref256","doi-asserted-by":"publisher","first-page":"868790","DOI":"10.3389\/fnmol.2022.868790","article-title":"Alpha-synuclein impacts on intrinsic neuronal network activity through reduced levels of cyclic AMP and diminished numbers of active presynaptic terminals","volume":"15","author":"Leite","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref257","doi-asserted-by":"publisher","first-page":"586453","DOI":"10.3389\/fnsyn.2020.586453","article-title":"Histone deacetylase 6 and the disease mechanisms of alpha-synucleinopathies","volume":"12","author":"Lemos","year":"2020","journal-title":"Front. Synaptic. Neurosci."},{"key":"ref258","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1016\/j.bmc.2017.04.038","article-title":"O-GlcNAc modification inhibits the calpain-mediated cleavage of alpha-synuclein","volume":"25","author":"Levine","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref259","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1073\/pnas.1808845116","article-title":"Alpha-synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease","volume":"116","author":"Levine","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref260","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1021\/acschembio.7b00113","article-title":"O-GlcNAcylation of alpha-synuclein at serine 87 reduces aggregation without affecting membrane binding","volume":"12","author":"Lewis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref261","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1101\/gad.1223504","article-title":"Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta","volume":"18","author":"Li","year":"2004","journal-title":"Genes Dev."},{"key":"ref262","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/BF02738829","article-title":"Effects of pinealectomy and melatonin on gonadotropin-releasing hormone (GnRH) gene expression in the male rat brain","volume":"3","author":"Li","year":"1995","journal-title":"Endocrine"},{"key":"ref263","doi-asserted-by":"publisher","first-page":"623977","DOI":"10.3389\/fnagi.2021.623977","article-title":"Alterations of erythrocytic phosphorylated alpha-synuclein in different subtypes and stages of Parkinson's disease","volume":"13","author":"Li","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref264","doi-asserted-by":"publisher","first-page":"8740419","DOI":"10.1155\/2020\/8740419","article-title":"Phosphorylated alpha-synuclein in red blood cells as a potential diagnostic biomarker for multiple system atrophy: a pilot study","volume":"2020","author":"Li","year":"2020","journal-title":"Parkinsons Dis."},{"key":"ref002","doi-asserted-by":"publisher","first-page":"697440","DOI":"10.3389\/fnmol.2021.697440","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing alpha-Synuclein and Oxidative Stress","volume":"14","author":"Lin","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"ref265","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/jcm8101601","article-title":"Plasma pS129-alpha-synuclein is a surrogate biofluid marker of motor severity and progression in Parkinson's disease","volume":"8","author":"Lin","year":"2019","journal-title":"J. Clin. Med."},{"key":"ref266","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease","volume":"101","author":"Liu","year":"","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref267","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/j.1460-9568.2007.05569.x","article-title":"Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII","volume":"25","author":"Liu","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref268","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1038\/sj.emboj.7600451","article-title":"Alpha-synuclein produces a long-lasting increase in neurotransmitter release","volume":"23","author":"Liu","year":"","journal-title":"EMBO J."},{"key":"ref269","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"ref270","doi-asserted-by":"publisher","first-page":"E7176","DOI":"10.1073\/pnas.1522332112","article-title":"cAMP-induced phosphorylation of 26S proteasomes on Rpn6\/PSMD11 enhances their activity and the degradation of misfolded proteins","volume":"112","author":"Lokireddy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref271","doi-asserted-by":"publisher","first-page":"5012129","DOI":"10.1155\/2017\/5012129","article-title":"The contribution of alpha-Synuclein spreading to Parkinson's Disease Synaptopathy","volume":"2017","author":"Longhena","year":"2017","journal-title":"Neural Plast."},{"key":"ref272","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/ijms20010141","article-title":"Living in promiscuity: the multiple Partners of alpha-synuclein at the synapse in physiology and pathology","volume":"20","author":"Longhena","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"ref273","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1034\/j.1600-079X.2003.00041.x","article-title":"Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions","volume":"34","author":"Lopez-Burillo","year":"2003","journal-title":"J. Pineal Res."},{"key":"ref274","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.biocel.2005.09.008","article-title":"Identification of an inducible nitric oxide synthase in diaphragm mitochondria from septic mice: its relation with mitochondrial dysfunction and prevention by melatonin","volume":"38","author":"Lopez","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref275","doi-asserted-by":"publisher","first-page":"10510","DOI":"10.1523\/JNEUROSCI.1659-16.2016","article-title":"Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase","volume":"36","author":"Ludtmann","year":"2016","journal-title":"J. Neurosci."},{"key":"ref276","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1073\/pnas.1200575109","article-title":"Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons","volume":"109","author":"Lundblad","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref277","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/JAD-2003-5208","article-title":"Alpha-synuclein aggregation and neurodegenerative diseases","volume":"5","author":"Ma","year":"2003","journal-title":"J. Alzheimers Dis."},{"key":"ref278","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1038\/s41598-020-65503-1","article-title":"Increased alpha-synuclein tear fluid levels in patients with Parkinson's disease","volume":"10","author":"Maass","year":"2020","journal-title":"Sci. Rep."},{"key":"ref279","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41531-022-00357-0","article-title":"Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies","volume":"8","author":"Magalhaes","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"ref280","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1749-6632.1996.tb34449.x","article-title":"Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders","volume":"777","author":"Magistretti","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref281","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","article-title":"C-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's disease","volume":"23","author":"Mahul-Mellier","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref282","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/mds.26754","article-title":"Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression","volume":"31","author":"Majbour","year":"","journal-title":"Mov. Disord."},{"key":"ref283","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","article-title":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease","volume":"11","author":"Majbour","year":"","journal-title":"Mol. Neurodegener."},{"key":"ref284","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ane.12247","article-title":"Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review","volume":"130","author":"Malek","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"ref285","author":"Mandhane","year":"2019"},{"key":"ref286","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/ana.410360612","article-title":"Complex I, iron, and ferritin in Parkinson's disease substantia nigra","volume":"36","author":"Mann","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref287","doi-asserted-by":"publisher","first-page":"690293","DOI":"10.3389\/fnagi.2021.690293","article-title":"Alpha-synuclein post-translational modifications: implications for pathogenesis of Lewy body disorders","volume":"13","author":"Manzanza","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref288","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nchem.2361","article-title":"O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson's disease","volume":"7","author":"Marotta","year":"2015","journal-title":"Nat. Chem."},{"key":"ref289","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1074\/mcp.RA117.000447","article-title":"Promyelocytic leukemia protein (PML) requirement for interferon-induced global cellular SUMOylation","volume":"17","author":"Maroui","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"ref290","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41531-023-00485-1","article-title":"DOPAL initiates alphaSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson's disease","volume":"9","author":"Masato","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"ref291","first-page":"147","article-title":"Interleukin 6 activities and tumor necrosis factor-alpha levels in serum of patients with Kawasaki disease","volume":"40","author":"Matsubara","year":"1991","journal-title":"Arerugi"},{"key":"ref292","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3177\/jnsv.65.S51","article-title":"Protective effect of tocotrienol on in vitro and in vivo models of Parkinson's disease","volume":"65","author":"Matsura","year":"2019","journal-title":"J. Nutr. Sci. Vitaminol. (Tokyo)"},{"key":"ref293","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1083\/jcb.135.6.1457","article-title":"A novel ubiquitin-like modification modulates the partitioning of the ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex","volume":"135","author":"Matunis","year":"1996","journal-title":"J. Cell Biol."},{"key":"ref294","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1093\/hmg\/ddr326","article-title":"The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS","volume":"20","author":"Maxwell","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref295","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","article-title":"Biomarkers: potential uses and limitations","volume":"1","author":"Mayeux","year":"2004","journal-title":"NeuroRx"},{"key":"ref296","doi-asserted-by":"publisher","first-page":"103642","DOI":"10.1016\/j.mcn.2021.103642","article-title":"LMK235, a small molecule inhibitor of HDAC4\/5, protects dopaminergic neurons against neurotoxin-and alpha-synuclein-induced degeneration in cellular models of Parkinson's disease","volume":"115","author":"Mazzocchi","year":"2021","journal-title":"Mol. Cell. Neurosci."},{"key":"ref297","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1074\/jbc.M109.081950","article-title":"Phosphorylation of synucleins by members of the polo-like kinase family","volume":"285","author":"Mbefo","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref298","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fncel.2017.00388","article-title":"Alpha-synuclein dimers impair vesicle fission during clathrin-mediated synaptic vesicle recycling","volume":"11","author":"Medeiros","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref299","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3390\/ijms17091585","article-title":"Protein kinases and Parkinson's disease","volume":"17","author":"Mehdi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"ref300","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3390\/nu12061616","article-title":"Nicotinamide Riboside-the current state of research and therapeutic uses","volume":"12","author":"Mehmel","year":"2020","journal-title":"Nutrients"},{"key":"ref301","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1039\/D1CB00220A","article-title":"Phosphorylated resveratrol as a protein aggregation suppressor in vitro and in vivo","volume":"3","author":"Mehringer","year":"2022","journal-title":"RSC Chem. Biol."},{"key":"ref302","doi-asserted-by":"publisher","first-page":"42942","DOI":"10.1038\/srep42942","article-title":"Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress","volume":"7","author":"Menges","year":"2017","journal-title":"Sci. Rep."},{"key":"ref303","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/biof.5520180208","article-title":"Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential","volume":"18","author":"Menke","year":"2003","journal-title":"Biofactors"},{"key":"ref304","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1468-1331.2010.03088.x","article-title":"Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan","volume":"18","author":"Miyake","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref305","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00702-001-0761-5","article-title":"Serum levels of coenzyme Q in patients with Lewy body disease","volume":"109","author":"Molina","year":"2002","journal-title":"J. Neural Transm. (Vienna)"},{"key":"ref306","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/mds.27090","article-title":"A user's guide for alpha-synuclein biomarker studies in biological fluids: Perianalytical considerations","volume":"32","author":"Mollenhauer","year":"2017","journal-title":"Mov. Disord."},{"key":"ref307","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neulet.2012.11.004","article-title":"Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects","volume":"532","author":"Mollenhauer","year":"2013","journal-title":"Neurosci. Lett."},{"key":"ref308","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/nano8020087","article-title":"Idebenone: novel strategies to improve its systemic and local efficacy","volume":"8","author":"Montenegro","year":"2018","journal-title":"Nanomaterials"},{"key":"ref309","doi-asserted-by":"publisher","first-page":"e0157602","DOI":"10.1371\/journal.pone.0157602","article-title":"N-acetyl cysteine may support dopamine neurons in Parkinson's disease: preliminary clinical and cell line data","volume":"11","author":"Monti","year":"2016","journal-title":"PLoS One"},{"key":"ref310","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","article-title":"Molecular pathophysiology of Parkinson's disease","volume":"28","author":"Moore","year":"2005","journal-title":"Annu. Rev. Neurosci."},{"key":"ref311","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/WNL.46.5.1270","article-title":"Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake","volume":"46","author":"Morens","year":"1996","journal-title":"Neurology"},{"key":"ref312","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cnr.2006.09.006","article-title":"Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's Disease","volume":"6","author":"Mosley","year":"2006","journal-title":"Clin. Neurosci. Res."},{"key":"ref313","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/35056591","article-title":"SUMO, ubiquitin's mysterious cousin","volume":"2","author":"Muller","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref314","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0891-0618(00)00096-X","article-title":"Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?","volume":"20","author":"Munch","year":"2000","journal-title":"J. Chem. Neuroanat."},{"key":"ref315","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1006\/bbrc.2000.4253","article-title":"Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125","volume":"280","author":"Nakamura","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref316","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2014.10.007","article-title":"Saxagliptin: a novel antiparkinsonian approach","volume":"89","author":"Nassar","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref317","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref318","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1586\/14737159.3.5.525","article-title":"Biomarkers: current perspectives and future prospects","volume":"3","author":"Naylor","year":"2003","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref319","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1096\/fj.01-0517fje","article-title":"Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation","volume":"16","author":"Negro","year":"2002","journal-title":"FASEB J."},{"key":"ref320","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s11064-011-0527-x","article-title":"Identification of novel alpha-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method","volume":"36","author":"Ohrfelt","year":"2011","journal-title":"Neurochem. Res."},{"key":"ref321","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1074\/jbc.275.1.390","article-title":"Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein","volume":"275","author":"Okochi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref322","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-021-00203-9","article-title":"Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease","volume":"7","author":"Oliveira","year":"2021","journal-title":"NPJ Parkinsons Dis."},{"key":"ref323","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.nbd.2006.10.010","article-title":"Vitamin a potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases","volume":"25","author":"Ono","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"ref324","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.expneurol.2004.05.035","article-title":"Vitamin a exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro","volume":"189","author":"Ono","year":"2004","journal-title":"Exp. Neurol."},{"key":"ref325","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.2174\/092986711796957257","article-title":"Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues","volume":"18","author":"Orsucci","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref326","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","article-title":"Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies","volume":"183","author":"Oueslati","year":"2010","journal-title":"Prog. Brain Res."},{"key":"ref327","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1523\/JNEUROSCI.3784-11.2012","article-title":"Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease","volume":"32","author":"Oueslati","year":"2012","journal-title":"J. Neurosci."},{"key":"ref328","doi-asserted-by":"publisher","first-page":"E3945","DOI":"10.1073\/pnas.1309991110","article-title":"Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo","volume":"110","author":"Oueslati","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref329","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1126\/science.1143780","article-title":"Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease","volume":"317","author":"Outeiro","year":"2007","journal-title":"Science"},{"key":"ref330","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"ref331","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson Disease: a phase 2 randomized clinical trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref332","doi-asserted-by":"publisher","first-page":"e00470","DOI":"10.1002\/prp2.470","article-title":"Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease","volume":"7","author":"Pagan","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref333","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1042\/bj3400821","article-title":"Copper(II)-induced self-oligomerization of alpha-synuclein","volume":"340","author":"Paik","year":"1999","journal-title":"Biochem. J."},{"key":"ref334","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1523\/JNEUROSCI.5922-09.2010","article-title":"Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions","volume":"30","author":"Paleologou","year":"2010","journal-title":"J. Neurosci."},{"key":"ref335","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbr.2017.01.004","article-title":"Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects","volume":"321","author":"Palleria","year":"2017","journal-title":"Behav. Brain Res."},{"key":"ref336","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1007\/s11011-022-01087-1","article-title":"AMPK-dependent autophagy activation and alpha-synuclein clearance: a putative mechanism behind alpha-mangostin's neuroprotection in a rotenone-induced mouse model of Parkinson's disease","volume":"37","author":"Parekh","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"ref337","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1074\/jbc.M115.675488","article-title":"Regulation of histone acetylation by autophagy in Parkinson disease","volume":"291","author":"Park","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref338","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref339","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson's disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref340","doi-asserted-by":"publisher","first-page":"8053","DOI":"10.1523\/JNEUROSCI.21-20-08053.2001","article-title":"Induction of alpha-synuclein aggregation by intracellular nitrative insult","volume":"21","author":"Paxinou","year":"2001","journal-title":"J. Neurosci."},{"key":"ref341","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cmet.2008.06.011","article-title":"Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span","volume":"8","author":"Pearson","year":"2008","journal-title":"Cell Metab."},{"key":"ref342","doi-asserted-by":"publisher","first-page":"2360872","DOI":"10.1155\/2020\/2360872","article-title":"Oxidative stress in Parkinson's Disease: potential benefits of antioxidant supplementation","volume":"2020","author":"Percario","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref343","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1021\/acschemneuro.2c00057","article-title":"O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for Tau and alpha-synuclein proteinopathies","volume":"13","author":"Permanne","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"ref344","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3233\/JPD-223285","article-title":"Comparative analysis of Total alpha-synuclein (alphaSYN) immunoassays reveals that they do not capture the diversity of modified alphaSYN proteoforms","volume":"12","author":"Petricca","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"ref345","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","article-title":"Non-motor symptoms in Parkinson's disease","volume":"22","author":"Pfeiffer","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref346","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/jcm9020504","article-title":"Mitochondrial signatures in circulating extracellular vesicles of older adults with Parkinson's disease: results from the EXosomes in PArkiNson's disease (EXPAND) study","volume":"9","author":"Picca","year":"2020","journal-title":"J. Clin. Med."},{"key":"ref347","doi-asserted-by":"publisher","first-page":"e001370","DOI":"10.1136\/bmjdrc-2020-001370","article-title":"Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis","volume":"8","author":"Ping","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref348","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.phrs.2015.11.024","article-title":"Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: therapeutic implications for Parkinson's disease","volume":"103","author":"Pinho","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref349","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fncom.2013.00013","article-title":"The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease","volume":"7","author":"Pissadaki","year":"2013","journal-title":"Front. Comput. Neurosci."},{"key":"ref350","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.parkreldis.2012.04.020","article-title":"Analysis of colonic alpha-synuclein pathology in multiple system atrophy","volume":"18","author":"Pouclet","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref351","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref352","doi-asserted-by":"publisher","first-page":"26515","DOI":"10.1074\/jbc.M003542200","article-title":"Synucleins are a novel class of substrates for G protein-coupled receptor kinases","volume":"275","author":"Pronin","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref353","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbrc.2009.06.142","article-title":"Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications","volume":"387","author":"Qing","year":"","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref354","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.bbrc.2009.10.126","article-title":"Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease","volume":"390","author":"Qing","year":"","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref355","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/0016-5085(84)90079-9","article-title":"Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease","volume":"87","author":"Qualman","year":"1984","journal-title":"Gastroenterology"},{"key":"ref356","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1042\/bj0260725","article-title":"Oxidations by the brain","volume":"26","author":"Quastel","year":"1932","journal-title":"Biochem. J."},{"key":"ref357","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/j.1476-5381.2012.02100.x","article-title":"Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit","volume":"167","author":"Rampersaud","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref358","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.neuropharm.2012.01.026","article-title":"The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD","volume":"62","author":"Rane","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref359","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1021\/tx9000557","article-title":"Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol","volume":"22","author":"Rees","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"ref360","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.nbd.2018.03.001","article-title":"Inflammation kinase PKR phosphorylates alpha-synuclein and causes alpha-synuclein-dependent cell death","volume":"115","author":"Reimer","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref361","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2478\/v10102-010-0030-2","article-title":"Melatonin combats molecular terrorism at the mitochondrial level","volume":"1","author":"Reiter","year":"2008","journal-title":"Interdiscip. Toxicol."},{"key":"ref362","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1749-6632.2003.tb07509.x","article-title":"Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke","volume":"993","author":"Reiter","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref363","first-page":"3","article-title":"Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants","volume":"23","author":"Reiter","year":"","journal-title":"Neuro Endocrinol. Lett."},{"key":"ref364","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/s0047-6374(01)00384-0","article-title":"Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin","volume":"123","author":"Reiter","year":"","journal-title":"Mech. Ageing Dev."},{"key":"ref365","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/153537020523000205","article-title":"When melatonin gets on your nerves: its beneficial actions in experimental models of stroke","volume":"230","author":"Reiter","year":"2005","journal-title":"Exp. Biol. Med."},{"key":"ref366","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/nan.12299","article-title":"Review: spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein","volume":"42","author":"Rey","year":"","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref367","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00401-017-1792-9","article-title":"Spread of aggregates after olfactory bulb injection of alpha-synuclein fibrils is associated with early neuronal loss and is reduced long term","volume":"135","author":"Rey","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref368","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1084\/jem.20160368","article-title":"Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease","volume":"213","author":"Rey","year":"","journal-title":"J. Exp. Med."},{"key":"ref369","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00401-013-1158-x","article-title":"Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration","volume":"126","author":"Richter-Landsberg","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref370","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/biom11050718","article-title":"Alpha-Synuclein and mitochondrial dysfunction in Parkinson's disease: the emerging role of VDAC","volume":"11","author":"Risiglione","year":"2021","journal-title":"Biomol. Ther."},{"key":"ref371","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1600-079X.2003.00092.x","article-title":"Regulation of antioxidant enzymes: a significant role for melatonin","volume":"36","author":"Rodriguez","year":"2004","journal-title":"J. Pineal Res."},{"key":"ref372","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1600-079X.2006.00416.x","article-title":"Chronic melatonin treatment reduces the age-dependent inflammatory process in senescence-accelerated mice","volume":"42","author":"Rodriguez","year":"2007","journal-title":"J. Pineal Res."},{"key":"ref373","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.tcb.2004.10.006","article-title":"The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases","volume":"14","author":"Ross","year":"2004","journal-title":"Trends Cell Biol."},{"key":"ref374","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1074\/jbc.M704809200","article-title":"Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells","volume":"283","author":"Rott","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref375","doi-asserted-by":"publisher","first-page":"13176","DOI":"10.1073\/pnas.1704351114","article-title":"SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation","volume":"114","author":"Rott","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref376","doi-asserted-by":"publisher","first-page":"e36768","DOI":"10.7554\/eLife.36768","article-title":"Depleting Trim28 in adult mice is well tolerated and reduces levels of alpha-synuclein and tau","volume":"7","author":"Rousseaux","year":"2018","journal-title":"elife"},{"key":"ref377","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.freeradbiomed.2013.10.008","article-title":"Alpha-synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease","volume":"67","author":"Ryan","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref378","doi-asserted-by":"publisher","first-page":"108173","DOI":"10.1016\/j.neuropharm.2020.108173","article-title":"Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging","volume":"175","author":"Ryu","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref379","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neulet.2017.05.059","article-title":"Blood-brain barrier disruption in diabetic mice is linked to Nrf2 signaling deficits: role of ABCB10?","volume":"653","author":"Sajja","year":"2017","journal-title":"Neurosci. Lett."},{"key":"ref380","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref381","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/ADR-200191","article-title":"Phosphodiesterase inhibitors for Alzheimer's disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale","volume":"4","author":"Sanders","year":"2020","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref382","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.12.051","article-title":"Telmisartan reduces progressive oxidative stress and phosphorylated alpha-synuclein accumulation in stroke-resistant spontaneously hypertensive rats after transient middle cerebral artery occlusion","volume":"23","author":"Sato","year":"2014","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref383","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1038\/ncomms5211","article-title":"Systemic regulation of mammalian ageing and longevity by brain sirtuins","volume":"5","author":"Satoh","year":"2014","journal-title":"Nat. Commun."},{"key":"ref384","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fnagi.2020.00167","article-title":"SUMOylation in alpha-Synuclein homeostasis and pathology","volume":"12","author":"Savyon","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref385","doi-asserted-by":"publisher","first-page":"221ra15","DOI":"10.1126\/scitranslmed.3007653","article-title":"Antioxidants accelerate lung cancer progression in mice","volume":"6","author":"Sayin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref386","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1007\/s11064-008-9855-x","article-title":"Mitochondrial dysfunction in neurodegenerative diseases","volume":"33","author":"Schapira","year":"2008","journal-title":"Neurochem. Res."},{"key":"ref387","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrneurol.2010.52","article-title":"Molecular and clinical prodrome of Parkinson disease: implications for treatment","volume":"6","author":"Schapira","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref388","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.870120209","article-title":"Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease","volume":"12","author":"Scheider","year":"1997","journal-title":"Mov. Disord."},{"key":"ref389","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.3390\/ijms21228637","article-title":"Efficacy of sulforaphane in neurodegenerative diseases","volume":"21","author":"Schepici","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref390","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fneur.2019.00148","article-title":"Dietary vitamin E as a protective factor for Parkinson's disease: clinical and experimental evidence","volume":"10","author":"Schirinzi","year":"2019","journal-title":"Front. Neurol."},{"key":"ref391","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","article-title":"Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies","volume":"12","author":"Schmid","year":"2013","journal-title":"Mol. Cell. Proteomics"},{"key":"ref392","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","article-title":"Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature","volume":"32","author":"Schneider","year":"2017","journal-title":"Mov. Disord."},{"key":"ref393","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.celrep.2018.05.009","article-title":"The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and Fly models of Parkinson's disease","volume":"23","author":"Schondorf","year":"2018","journal-title":"Cell Rep."},{"key":"ref394","doi-asserted-by":"publisher","first-page":"10062","DOI":"10.1021\/acs.jmedchem.9b01090","article-title":"Discovery of MK-8719, a potent O-GlcNAcase inhibitor as a potential treatment for Tauopathies","volume":"62","author":"Selnick","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref395","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.molcel.2012.07.011","article-title":"The size of the proteasomal substrate determines whether its degradation will be mediated by mono-or polyubiquitylation","volume":"48","author":"Shabek","year":"2012","journal-title":"Mol. Cell"},{"key":"ref396","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2174\/1389200217666151222155216","article-title":"Methylglyoxal, a metabolite increased in diabetes is associated with insulin resistance, vascular dysfunction and neuropathies","volume":"17","author":"Shamsaldeen","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"ref397","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/mds.23838","article-title":"Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease","volume":"27","author":"Shannon","year":"2012","journal-title":"Mov. Disord."},{"key":"ref398","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12031-014-0461-x","article-title":"Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice","volume":"56","author":"Sharma","year":"","journal-title":"J. Mol. Neurosci."},{"key":"ref399","doi-asserted-by":"publisher","first-page":"12531","DOI":"10.1038\/srep12531","article-title":"Insulin-degrading enzyme prevents alpha-synuclein fibril formation in a nonproteolytical manner","volume":"5","author":"Sharma","year":"","journal-title":"Sci. Rep."},{"key":"ref400","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bbrc.2015.09.002","article-title":"Insulin-degrading enzyme is activated by the C-terminus of alpha-synuclein","volume":"466","author":"Sharma","year":"","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref401","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jnr.20082","article-title":"1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells","volume":"76","author":"Shavali","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"ref402","doi-asserted-by":"publisher","first-page":"10756","DOI":"10.1523\/JNEUROSCI.23-34-10756.2003","article-title":"Mechanism of toxicity in rotenone models of Parkinson's disease","volume":"23","author":"Sherer","year":"2003","journal-title":"J. Neurosci."},{"key":"ref403","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000134061","article-title":"High-resolution mapping of SNCA encoding alpha-synuclein, the non-A beta component of Alzheimer's disease amyloid precursor, to human chromosome 4q21.3-->q22 by fluorescence in situ hybridization","volume":"71","author":"Shibasaki","year":"1995","journal-title":"Cytogenet. Cell Genet."},{"key":"ref404","doi-asserted-by":"publisher","first-page":"105509","DOI":"10.1016\/j.nbd.2021.105509","article-title":"Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy","volume":"159","author":"Shukla","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"ref405","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2005.02.002","article-title":"Therapeutic role of coenzyme Q(10) in Parkinson's disease","volume":"107","author":"Shults","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"ref406","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/ana.410420221","article-title":"Coenzyme Q10 levels correlate with the activities of complexes I and II\/III in mitochondria from parkinsonian and nonparkinsonian subjects","volume":"42","author":"Shults","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref407","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/WNL.57.3.375","article-title":"A cue to queue for CoQ?","volume":"57","author":"Shults","year":"2001","journal-title":"Neurology"},{"key":"ref408","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13578-021-00709-y","article-title":"Alpha-synuclein-mediated neurodegeneration in dementia with Lewy bodies: the pathobiology of a paradox","volume":"11","author":"Simon","year":"2021","journal-title":"Cell Biosci."},{"key":"ref409","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of Nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref410","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1158\/0008-5472.CAN-08-1401","article-title":"RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res."},{"key":"ref411","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1093\/hmg\/ddi396","article-title":"Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity","volume":"14","author":"Smith","year":"","journal-title":"Hum. Mol. Genet."},{"key":"ref412","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1523\/JNEUROSCI.0482-05.2005","article-title":"Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells","volume":"25","author":"Smith","year":"","journal-title":"J. Neurosci."},{"key":"ref413","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jns.2004.05.007","article-title":"Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease","volume":"223","author":"Sohmiya","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"ref414","doi-asserted-by":"publisher","first-page":"e0272085","DOI":"10.1371\/journal.pone.0272085","article-title":"NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-alpha-synuclein mouse model of Parkinson's disease","volume":"17","author":"Song","year":"2022","journal-title":"PLoS One"},{"key":"ref415","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/cells11050906","article-title":"Pathological relevance of Post-Translationally modified alpha-synuclein (pSer87, pSer129, nTyr39) in idiopathic Parkinson's Disease and multiple system atrophy","volume":"11","author":"Sonustun","year":"2022","journal-title":"Cells"},{"key":"ref416","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.bbrc.2017.06.156","article-title":"Structural bases of the altered catalytic properties of a pathogenic variant of apoptosis inducing factor","volume":"490","author":"Sorrentino","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref417","doi-asserted-by":"publisher","first-page":"18344","DOI":"10.1074\/jbc.M000206200","article-title":"Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies","volume":"275","author":"Souza","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref418","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1353-8020(99)00031-0","article-title":"Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies","volume":"5","author":"Spillantini","year":"1999","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref419","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref420","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nan.12311","article-title":"Synucleinopathies: past, present and future","volume":"42","author":"Spillantini","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref421","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"ref422","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1212\/WNL.0000000000002126","article-title":"Enteric nervous system alpha-synuclein immunoreactivity in idiopathic REM sleep behavior disorder","volume":"85","author":"Sprenger","year":"2015","journal-title":"Neurology"},{"key":"ref423","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.neuroscience.2013.04.037","article-title":"Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease","volume":"246","author":"St Laurent","year":"2013","journal-title":"Neuroscience"},{"key":"ref424","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"Alpha-synuclein in Parkinson's disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref425","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/jnc.14704","article-title":"How is alpha-synuclein cleared from the cell?","volume":"150","author":"Stefanis","year":"2019","journal-title":"J. Neurochem."},{"key":"ref426","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3390\/nu6093777","article-title":"Dietary regulation of Keap1\/Nrf2\/ARE pathway: focus on plant-derived compounds and trace minerals","volume":"6","author":"Stefanson","year":"2014","journal-title":"Nutrients"},{"key":"ref427","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","article-title":"Phosphorylated alpha-synuclein in Parkinson's disease: correlation depends on disease severity","volume":"3","author":"Stewart","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"ref428","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1474-4422(16)30031-X","article-title":"Salivary gland biopsy for diagnosis of Parkinson's disease?","volume":"15","author":"Stoessl","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref429","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.24648","article-title":"Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients","volume":"79","author":"Stokholm","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref430","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2007.05.018","article-title":"Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats","volume":"569","author":"Sudnikovich","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"ref431","doi-asserted-by":"publisher","first-page":"23179","DOI":"10.1074\/jbc.M802223200","article-title":"Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death","volume":"283","author":"Sugeno","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref432","doi-asserted-by":"publisher","first-page":"17237","DOI":"10.1074\/jbc.C000099200","article-title":"Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species","volume":"275","author":"Sun","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref433","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuropharm.2015.07.015","article-title":"NRSF is an essential mediator for the neuroprotection of trichostatin a in the MPTP mouse model of Parkinson's disease","volume":"99","author":"Suo","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref434","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study","volume":"31","author":"Svenningsson","year":"2016","journal-title":"Mov. Disord."},{"key":"ref435","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0304-3940(02)01258-2","article-title":"Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila","volume":"336","author":"Takahashi","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref436","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0006-8993(02)02498-8","article-title":"Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress","volume":"938","author":"Takahashi","year":"2002","journal-title":"Brain Res."},{"key":"ref437","doi-asserted-by":"publisher","first-page":"5789424","DOI":"10.1155\/2018\/5789424","article-title":"Motor and nonmotor symptoms of Parkinson's disease: antagonistic pleiotropy phenomena derived from alpha-synuclein evolvability?","volume":"2018","author":"Takamatsu","year":"2018","journal-title":"Parkinsons Dis."},{"key":"ref438","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-020-02233-8","article-title":"Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases","volume":"141","author":"Tanei","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref439","doi-asserted-by":"publisher","first-page":"35368","DOI":"10.1074\/jbc.M104214200","article-title":"Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1\/SAE2 and Ubc9","volume":"276","author":"Tatham","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref440","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/febs.15349","article-title":"Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of alpha-synuclein preformed fibrils","volume":"288","author":"Tavassoly","year":"2021","journal-title":"FEBS J."},{"key":"ref441","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.3390\/ijms23115938","article-title":"An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases","volume":"23","author":"Teleanu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"ref442","doi-asserted-by":"publisher","first-page":"e1004302","DOI":"10.1371\/journal.pgen.1004302","article-title":"Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease","volume":"10","author":"Tenreiro","year":"2014","journal-title":"PLoS Genet."},{"key":"ref443","doi-asserted-by":"publisher","first-page":"17962","DOI":"10.1074\/jbc.M802283200","article-title":"CHIP targets toxic alpha-Synuclein oligomers for degradation","volume":"283","author":"Tetzlaff","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref444","doi-asserted-by":"publisher","first-page":"947191","DOI":"10.3389\/fnmol.2022.947191","article-title":"The relationship of alpha-synuclein to mitochondrial dynamics and quality control","volume":"15","author":"Thorne","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref445","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40035-019-0155-y","article-title":"Erythrocytic alpha-Synuclein as a potential biomarker for Parkinson's disease","volume":"8","author":"Tian","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"ref446","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1073\/pnas.1109356108","article-title":"Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway","volume":"108","author":"Tofaris","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref447","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0014-5793(01)03115-5","article-title":"Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome","volume":"509","author":"Tofaris","year":"2001","journal-title":"FEBS Lett."},{"key":"ref448","doi-asserted-by":"publisher","first-page":"44405","DOI":"10.1074\/jbc.M308041200","article-title":"Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function","volume":"278","author":"Tofaris","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref449","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-021-00450-7","article-title":"Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain","volume":"16","author":"Toker","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref450","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"ref451","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3233\/JAD-2010-1271","article-title":"Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg","volume":"19","author":"Tremblay","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"ref452","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/mds.27132","article-title":"Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease","volume":"32","author":"Trezzi","year":"2017","journal-title":"Mov. Disord."},{"key":"ref453","doi-asserted-by":"publisher","first-page":"135624","DOI":"10.1016\/j.scitotenv.2019.135624","article-title":"Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders","volume":"707","author":"Uddin","year":"2020","journal-title":"Sci. Total Environ."},{"key":"ref454","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"Ueda","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref455","doi-asserted-by":"publisher","first-page":"19536","DOI":"10.1021\/ja208657z","article-title":"Explaining the structural plasticity of alpha-synuclein","volume":"133","author":"Ullman","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref456","doi-asserted-by":"publisher","first-page":"e0255726","DOI":"10.1371\/journal.pone.0255726","article-title":"GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: translational systematic review and meta-analysis protocol of clinical and preclinical studies","volume":"16","author":"Vaccari","year":"2021","journal-title":"PLoS One"},{"key":"ref457","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2009.03.021","article-title":"The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast","volume":"389","author":"Vamvaca","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref458","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2174\/187152711797247858","article-title":"Kinases as targets for Parkinson's disease: from genetics to therapy","volume":"10","author":"Vancraenenbroeck","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref459","doi-asserted-by":"publisher","first-page":"13713","DOI":"10.1038\/s41598-017-14175-5","article-title":"Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease","volume":"7","author":"Vicente Miranda","year":"","journal-title":"Sci. Rep."},{"key":"ref460","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/path.2682","article-title":"The sour side of neurodegenerative disorders: the effects of protein glycation","volume":"221","author":"Vicente Miranda","year":"2010","journal-title":"J. Pathol."},{"key":"ref461","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/brain\/awx056","article-title":"Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies","volume":"140","author":"Vicente Miranda","year":"","journal-title":"Brain"},{"key":"ref462","doi-asserted-by":"publisher","first-page":"103416","DOI":"10.1016\/j.mcn.2019.103416","article-title":"Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates","volume":"101","author":"Vijayakumaran","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"ref463","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S1474-4422(16)00080-6","article-title":"Assessment of alpha-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study","volume":"15","author":"Vilas","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref464","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mds.29246","article-title":"Salivary alpha-synuclein RT-QuIC correlates with disease severity in de novo Parkinson's disease","volume":"38","author":"Vivacqua","year":"2023","journal-title":"Mov. Disord."},{"key":"ref465","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.parkreldis.2019.02.014","article-title":"Salivary alpha-synuclein in the diagnosis of Parkinson's disease and progressive supranuclear palsy","volume":"63","author":"Vivacqua","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref466","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"Wahlqvist","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref467","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/neup.12691","article-title":"Where and how alpha-synuclein pathology spreads in Parkinson's disease","volume":"40","author":"Wakabayashi","year":"2020","journal-title":"Neuropathology"},{"key":"ref468","article-title":"Neuropathology of multiple system atrophy, a glioneuronal degenerative disease","volume-title":"Cerebellum","author":"Wakabayashi","year":"2022"},{"key":"ref469","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bpa.12647","article-title":"Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1","volume":"29","author":"Wang","year":"2019","journal-title":"Brain Pathol."},{"key":"ref470","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1369\/0022155420960250","article-title":"Phosphorylated alpha-synuclein within cutaneous autonomic nerves of patients with Parkinson's disease: the implications of sample thickness on results","volume":"68","author":"Wang","year":"","journal-title":"J. Histochem. Cytochem."},{"key":"ref471","doi-asserted-by":"publisher","first-page":"17797","DOI":"10.1073\/pnas.1113260108","article-title":"A soluble alpha-synuclein construct forms a dynamic tetramer","volume":"108","author":"Wang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref472","doi-asserted-by":"publisher","first-page":"e89353","DOI":"10.1371\/journal.pone.0116382","article-title":"Using gastrocnemius sEMG and plasma alpha-synuclein for the prediction of freezing of gait in Parkinson's disease patients","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"ref473","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","volume":"78","author":"Wang","year":"","journal-title":"JAMA Neurol."},{"key":"ref474","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.neuroscience.2009.01.021","article-title":"Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein","volume":"159","author":"Watson","year":"2009","journal-title":"Neuroscience"},{"key":"ref475","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jnr.22537","article-title":"Characterization of kinases involved in the phosphorylation of aggregated alpha-synuclein","volume":"89","author":"Waxman","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"ref476","doi-asserted-by":"publisher","first-page":"25009","DOI":"10.1074\/jbc.M300227200","article-title":"Alpha-Synuclein is degraded by both autophagy and the proteasome","volume":"278","author":"Webb","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref477","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neulet.2013.03.057","article-title":"Increased SUMO-1 expression in the unilateral rotenone-lesioned mouse model of Parkinson's disease","volume":"544","author":"Weetman","year":"2013","journal-title":"Neurosci. Lett."},{"key":"ref478","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/35056563","article-title":"Themes and variations on ubiquitylation","volume":"2","author":"Weissman","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref479","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.mito.2013.01.006","article-title":"Regulation of mitochondrial biogenesis and PGC-1alpha under cellular stress","volume":"13","author":"Wenz","year":"2013","journal-title":"Mitochondrion"},{"key":"ref480","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.28858","article-title":"Parkinson's disease modification through Abl kinase inhibition: an opportunity","volume":"37","author":"Werner","year":"2022","journal-title":"Mov. Disord."},{"key":"ref481","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.neuint.2013.02.004","article-title":"Toxicity of extracellular secreted alpha-synuclein: its role in nitrosative stress and neurodegeneration","volume":"62","author":"Wilkaniec","year":"2013","journal-title":"Neurochem. Int."},{"key":"ref482","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1042\/BJ20100158","article-title":"Mechanisms, regulation and consequences of protein SUMOylation","volume":"428","author":"Wilkinson","year":"2010","journal-title":"Biochem. J."},{"key":"ref483","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1152\/jn.2000.83.5.3084","article-title":"Coupled oscillator model of the dopaminergic neuron of the substantia nigra","volume":"83","author":"Wilson","year":"2000","journal-title":"J. Neurophysiol."},{"key":"ref484","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1600-079X.2005.00295.x","article-title":"Melatonin attenuates diabetes-induced oxidative stress in rabbits","volume":"40","author":"Winiarska","year":"2006","journal-title":"J. Pineal Res."},{"key":"ref485","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbadis.2009.08.013","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"1802","author":"Winklhofer","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref486","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/mds.22464","article-title":"Biopsies of olfactory epithelium in patients with Parkinson's disease","volume":"24","author":"Witt","year":"2009","journal-title":"Mov. Disord."},{"key":"ref487","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1038\/nutd.2015.6","article-title":"Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males","volume":"5","author":"Wu","year":"2015","journal-title":"Nutr. Diabetes"},{"key":"ref488","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejogrb.2007.02.014","article-title":"Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells","volume":"137","author":"Wu","year":"2008","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref489","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jad.2019.11.147","article-title":"Nicotinamide mononucleotide ameliorates the depression-like behaviors and is associated with attenuating the disruption of mitochondrial bioenergetics in depressed mice","volume":"263","author":"Xie","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref490","doi-asserted-by":"publisher","first-page":"e5921","DOI":"10.1097\/MD.0000000000009419","article-title":"Increased risk of Parkinson disease with diabetes mellitus in a population-based study","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"ref491","doi-asserted-by":"publisher","first-page":"e35277","DOI":"10.1371\/journal.pone.0051967","article-title":"Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS One"},{"key":"ref492","doi-asserted-by":"publisher","first-page":"e9956","DOI":"10.1371\/journal.pone.0015623","article-title":"Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats","volume":"5","author":"Yu","year":"2010","journal-title":"PLoS One"},{"key":"ref003","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","article-title":"Biopsiesalpha-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism","volume":"13","author":"Yun","year":"2018","journal-title":"Mol Neurodegener."},{"key":"ref493","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.jmb.2014.01.004","article-title":"O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers","volume":"426","author":"Yuzwa","year":"","journal-title":"J. Mol. Biol."},{"key":"ref494","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nchembio.96","article-title":"A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo","volume":"4","author":"Yuzwa","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"ref495","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-9-42","article-title":"Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau\/APP mutant mice","volume":"9","author":"Yuzwa","year":"","journal-title":"Mol. Neurodegener."},{"key":"ref496","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nchembio.797","article-title":"Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation","volume":"8","author":"Yuzwa","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref497","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/brain\/awv138","article-title":"Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy","volume":"138","author":"Zange","year":"2015","journal-title":"Brain"},{"key":"ref498","doi-asserted-by":"publisher","first-page":"22460","DOI":"10.1074\/jbc.M702439200","article-title":"Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6","volume":"282","author":"Zhang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref499","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2017.06.034","article-title":"Enzymatic O-GlcNAcylation of alpha-synuclein reduces aggregation and increases SDS-resistant soluble oligomers","volume":"655","author":"Zhang","year":"2017","journal-title":"Neurosci. Lett."},{"key":"ref500","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fnins.2019.00381","article-title":"The roles of post-translational modifications on alpha-synuclein in the pathogenesis of Parkinson's diseases","volume":"13","author":"Zhang","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref501","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0002-9440(10)65396-5","article-title":"Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons","volume":"154","author":"Zhang","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref502","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1039\/C8FO00964C","article-title":"Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T alpha-synuclein mouse model of Parkinson's disease","volume":"9","author":"Zhang","year":"2018","journal-title":"Food Funct."},{"key":"ref503","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.4103\/1673-5374.303045","article-title":"Glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model","volume":"16","author":"Zhang","year":"2021","journal-title":"Neural Regen. Res."},{"key":"ref504","doi-asserted-by":"publisher","first-page":"12564","DOI":"10.1038\/srep12564","article-title":"LK6\/Mnk2a is a new kinase of alpha synuclein phosphorylation mediating neurodegeneration","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref505","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.fct.2013.05.058","article-title":"Antioxidant and Nrf2 inducing activities of luteolin, a flavonoid constituent in Ixeris sonchifolia Hance, provide neuroprotective effects against ischemia-induced cellular injury","volume":"59","author":"Zhang","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"ref506","doi-asserted-by":"publisher","first-page":"9426867","DOI":"10.1155\/2019\/9426867","article-title":"Benefits of vitamins in the treatment of Parkinson's Disease","volume":"2019","author":"Zhao","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref507","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12264-017-0179-1","article-title":"Age-dependent alpha-synuclein accumulation and phosphorylation in the enteric nervous system in a transgenic mouse model of Parkinson's disease","volume":"33","author":"Zhong","year":"2017","journal-title":"Neurosci. Bull."},{"key":"ref508","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.3892\/mmr.2014.2548","article-title":"Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells","volume":"10","author":"Zhou","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref509","doi-asserted-by":"publisher","first-page":"14941","DOI":"10.1074\/jbc.M110.211029","article-title":"Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease","volume":"286","author":"Zhou","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref510","doi-asserted-by":"publisher","first-page":"32262","DOI":"10.1074\/jbc.M404173200","article-title":"Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses","volume":"279","author":"Zhou","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref511","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","article-title":"A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease","volume":"89","author":"Zimprich","year":"2011","journal-title":"Am. J. Hum. Genet."}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2023.1197853\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:15:45Z","timestamp":1684973745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2023.1197853\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":514,"alternative-id":["10.3389\/fnmol.2023.1197853"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2023.1197853","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"article-number":"1197853"}}